SCHEMBL6715474

SCHEMBL6715474

Cc1cccc(C)c1NC(=O)[C@H](NC(=S)Nc1ccccc1C(F)(F)F)C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.48
ALOX12 P18054 7/20 0.48
PYGL P06737 2/20 0.46
POLB P06746 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
MAPT P10636 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
PLA2G1B P04054 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44
LMNA P02545 3/20 0.43
HPGD P15428 2/20 0.43
EPHX2 P34913 1/20 0.43
TP53 P04637 1/20 0.43
GAA P10253 2/20 0.42
CYP3A4 P08684 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8334912 0.79 KMT2A (0.53) ALDH1A1ALOX12PYGLCYP1A2CYP2C19
SCHEMBL6716815 0.79 ALDH1A1 (0.53) ALDH1A1ALOX12POLBNPSR1MAPT
SCHEMBL6715476 0.78 POLB (0.43) ALDH1A1ALOX12PYGLPOLBCYP1A2
SCHEMBL6717319 0.77 ALDH1A1 (0.54) ALDH1A1ALOX12POLBNPSR1MAPT
SCHEMBL8336155 0.74 KMT2A (0.48) PYGLLMNAEPHX2GAASMN1; SMN2
SCHEMBL6716913 0.74 ALDH1A1 (0.47) ALDH1A1ALOX12POLBNPSR1MAPT
SCHEMBL6723568 0.73 ALDH1A1 (0.51) ALDH1A1ALOX12PYGLMAPTLMNA
SCHEMBL6723186 0.73 ALDH1A1 (0.51) ALDH1A1ALOX12PYGLMAPTLMNA
SCHEMBL6718749 0.73 MEN1 (0.51) ALDH1A1PYGLPOLBNPSR1MAPT
SCHEMBL6716820 0.73 MEN1 (0.51) ALDH1A1PYGLPOLBNPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ALDH1A1 572/4885ALOX12 2690/4885PYGL 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.